Breaking News Instant updates and real-time market news.

CLVS

Clovis

$98.02

5.77 (6.25%)

, BMY

Bristol-Myers

$56.83

1.564 (2.83%)

11:10
07/31/17
07/31
11:10
07/31/17
11:10

Clovis slides as partnership seen raising doubt on takeover chances

Shares of Clovis (CLVS) are slipping after the company announced that it has entered into a clinical collaboration agreement to evaluate a combination of Bristol-Myers' (BMY) drug Opdivo and Clovis' drug Rubraca in cancer clinical trials. While Leerink analyst Michael Schmidt believes the deal does not preclude a future acquisition of Clovis, his peer at Janney Capital argued that this partnership "undercuts" the M&A thesis. PARTNERSHIP: Bristol-Myers Squibb and Clovis Oncology announced that they have entered into a clinical collaboration agreement to evaluate the combination of the former's immunotherapy Opdivo and the latter's "PARP, inhibitor" Rubraca in pivotal phase 3 clinical trials. In advanced ovarian cancer, the collaboration will include a first-line maintenance treatment study to evaluate Rubraca + Opdivo, Rubraca, Opdivo and placebo in newly diagnosed patients with stage III/IV high-grade ovarian, fallopian tube, or primary peritoneal cancer who have completed platinum-based chemotherapy, while in advanced triple-negative breast cancers it will include a first-line maintenance treatment study to evaluate Rubraca + Opdivo, Rubraca, Opdivo and chemotherapy in patients with stage IV or recurrent locally advanced inoperable TNBC associated with a homologous recombination deficiency. The partnership will also include a Phase 2 study to evaluate the safety and efficacy of Opdivo in combination with Rubraca in patients with metastatic castration-resistant prostate cancer. WEAKNESS UNWARRANTED: Following the announcement, Leerink analyst Michael Schmidt told investors in a research note that he believes today's weakness in Clovis is "unwarranted" and presents a buying opportunity. The analyst sees the deal as positive, providing Clovis with access to one of the leading approved PD1 inhibitors and access to Bristol-Myers' clinical development infrastructure, while only incurring about 50% of the development cost. While Schmidt acknowledged that some investors may have hoped for an outright acquisition of Clovis by Bristol-Myers in the near-term, he argued that this deal does not preclude a future acquisition of the company and increases the competitiveness and value of Rubraca. The analyst reiterated an Outperform rating on Clovis' shares. PARTNERSHIP UNDERCUTS M&A THESIS: Also commenting on the news, Janney Capital analyst Debjit Chattopadhyay told investors that Clovis' clinical partnership with Bristol-Myers undercuts his takeout thesis. Citing other PARP inhibitor deals between AstraZeneca (AZN)/Merck (MRK) and Tesaro (TSRO)/Takeda (TKPYY), the analyst argued that these recent agreements across the PARP space implies no near-term takeovers, which will likely be "disappointing to many." Chattopadhyay reiterated a Buy rating and a $107 price target on Clovis' shares, while noting that unlike peer transactions, there was no monetary component to the Bristol-Myers clinical partnership and Clovis retains full rights to Rubraca. PRICE ACTION: In morning trading, shares of Clovis have dropped almost 10% to $88.30, while Bristol-Myers has gained over 3% to $57.10 per share.

CLVS

Clovis

$98.02

5.77 (6.25%)

BMY

Bristol-Myers

$56.83

1.564 (2.83%)

AZN

AstraZeneca

$30.71

0.44 (1.45%)

MRK

Merck

$63.76

-0.35 (-0.55%)

TSRO

Tesaro

$134.15

7.45 (5.88%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$26.30

0.645 (2.51%)

  • 01

    Aug

  • 02

    Aug

  • 08

    Aug

  • 28

    Aug

  • 11

    Sep

  • 22

    Sep

  • 24

    Sep

  • 09

    Nov

  • 05

    Mar

CLVS Clovis
$98.02

5.77 (6.25%)

07/31/17
JPMS
07/31/17
NO CHANGE
JPMS
Clovis takeover thesis not off the table, says JPMorgan
JPMorgan said the Clovis (CLVS) and Bristol-Myers (BMY) collaboration does not impact the takeover thesis of Clovis. Analyst Cory Kasimov said the the no-strings-attached clinical collaboration has no financial terms aside from provision of study drug and sharing of trial costs in some instances and Bristol does not have first rights of refusal if an interested party did approach Clovis.
07/27/17
JANY
07/27/17
NO CHANGE
Target $107
JANY
Buy
PARP deals may make Clovis more attractive buyout candidate, says Janney
The partnerships announced today between AstraZeneca (AZN) and Merck (MRK) as well as Tesaro (TSRO) and Takeda highlight pharma's willingness to expand on PARP's, Janney analyst Debjit Chattopadhyay tells investors in a research note. Clovis' (CLVS) Rubraca is now the only unencumbered PARP and is "far cheaper" on a relative valuation basis than peer Tesaro, the analyst adds. He believes Clovis could now become a more compelling takeover candidate. Chattopadhyay has a Buy rating on the shares with a $107 price target. The stock in midday trading is up 7%, or $5.90, to $93.33.
07/31/17
LEER
07/31/17
NO CHANGE
LEER
Outperform
Clovis weakness unwarranted after Bristol-Myers pact, says Leerink
Leerink analyst Michael Schmidt thinks today's weakness in Clovis (CLVS) is unwarranted following the company's clinical collaboration agreement with Bristol-Myers (BMY) and presents a buying opportunity. This deal does not preclude a future acquisition of the company, but it does increase the competitiveness and value of Rubraca, argues Schmidt, who reiterates his Outperform rating on Clovis shares.
07/31/17
JANY
07/31/17
NO CHANGE
Target $107
JANY
Buy
Clovis partnership undercuts takeover thesis, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay says Clovis Oncology's (CLVS) clinical partnership with Bristol-Myer Squibb (BMY) undercuts his takeout thesis. The recent agreements across the PARP drugs implies no near-term takeovers, Chattopadhyay tells investors in a research note. He believes this will "likely to be disappointing to many." The analyst has a Buy rating on Clovis with a $107 price target. The shares in early trading are down $8.04, or 8% to $89.97.
BMY Bristol-Myers
$56.83

1.564 (2.83%)

07/28/17
LEER
07/28/17
NO CHANGE
Target $61
LEER
Outperform
Bristol-Myers price target lowered to $61 after Astra trial setback at Leerink
Leerink analyst Seamus Fernandez said Bristol-Myers (BMY) reported "solid" Q2 results, including encouraging growth for its key franchises, but he sees increased uncertainty following the failure of AstraZeneca's (AZN) MYSTIC trial, which has potential read through to Bristol's CheckMate-227 trial of its I/O combo of Opdivo + Yervoy. Fernandez lowered his price target on Bristol shares to $61 from $66, but "fully acknowledges" the range of differences in the trial designs. He keeps an Outperform rating on Bristol-Myers, citing prospects for monotherapy Opdivo approval in the second-line setting and success in first-line liver cancer.
07/27/17
LEER
07/27/17
NO CHANGE
LEER
Outperform
AstraZeneca trial failure negative for Bristol-Myers, says Leerink
Leerink analyst Seamus Fernandez notes that AstraZeneca (AZN) announced that the MYSTIC trial failed to show a progression-free survival benefit for Imfinzi + tremelimumab compared to chemotherapy in first-line non-small cell lung cancer patients with PDL1 expression greater than 25%. The read through is an obvious negative readthrough for Bristol-Myers' (BMY) combo of Opdivo + Yervoy in the ongoing CheckMate-227 trial, the analyst says. He points out that while there are several key differences in trial design between MYSTIC and CM-227, they are unlikely to result in meaningfully different outcomes. Fernandez reiterates an Outperform rating on Bristol-Myers' shares.
AZN AstraZeneca
$30.71

0.44 (1.45%)

07/28/17
07/28/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Starbucks (SBUX) was downgraded to Neutral from Buy at Guggenheim and to Hold from Buy at Stifel. 2. Spirit Airlines (SAVE) was downgraded to Neutral from Buy at Buckingham and BofA/Merrill and to In-Line from Outperform at Imperial Capital. 3. Flowers Foods (FLO) downgraded to Hold from Buy at Jefferies with analyst Akshay Jagdale saying his positive thesis on bread industry pricing becoming more rational has not played out. 4. AstraZeneca (AZN) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Vincent Meunier saying shares look fairly valued as he removed MYSTIC from his models. 5. U.S. Steel (X) downgraded to Sell from Neutral at Citi with analyst Alexander Hacking saying he sees downside risk to U.S. flat rolled prices for the remainder of 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/28/17
RHCO
07/28/17
NO CHANGE
RHCO
Merck, AstraZeneca deal positive, says SunTrust
After Merck (MRK) paid $1.6B upfront for access to Astrazeneca's (AZN) PARP inhibitor, Lynparza and another drug, SunTrust analyst John Boris says that the deal "makes strategic/financial sense and validates the PARP inhibitor class." He adds that the companies are "ideally positioned" to leverage a combination of IO and PARP therapies. The analyst reiterates a $73 price target and a Buy rating on Merck.
07/28/17
MSCO
07/28/17
DOWNGRADE
MSCO
Equal Weight
AstraZeneca downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Vincent Meunier downgraded AstraZeneca to Equal Weight saying shares look fairly valued as he removed MYSTIC from his models. The analyst said AstraZeneca has lower margin recovery prospects and reduced optionality from the pipeline near-term.
MRK Merck
$63.76

-0.35 (-0.55%)

07/27/17
FBCO
07/27/17
NO CHANGE
FBCO
Merck unlikely to buy PARP company after Astra deal, says Credit Suisse
Credit Suisse analyst Alethia Young believes Merck (MRK) is unlikely to acquire a PARP inhibitor company like Tesaro (TSRO) or Clovis (CLVS) after inking an immuno-oncology deal with AstraZeneca (AZN).
07/27/17
GSCO
07/27/17
NO CHANGE
GSCO
Merck could trade up $5 following AstraZeneca MYSTIC failure, says Goldman Sachs
Goldman analyst Jami Rubin expects Merck (MRK) to trade up approximately $5 based on sentiment following AstraZeneca's MYSTIC failure as it partially de-risks longer-term estimates for Keytruda. As a result, the analyst raised Merck's Keytruda sales estimates by $600M in 2018 and $1B in 2019 and beyond, increasing earnings estimates by 14c-20c, and raising his price target on shares to $74 from $70. Rubin cautions that long-term estimates could be at risk if other competitor trials are successful. The analyst rates Merck a Neutral.
TSRO Tesaro
$134.15

7.45 (5.88%)

07/14/17
SBSH
07/14/17
NO CHANGE
Target $216
SBSH
Buy
Citi reiterates $180 per share standalone valuation for Tesaro
After CNBC yesterday morning reported that a sale of Tesaro is unlikely, Citi analyst Robyn Karnauskas reiterated her $180 per share standalone valuation for the company. The analyst believes Niraparib is competitive in the PARP space and sees upside to the current share price. Her $216 price target is based on 60% standalone and 40% takeover potential. Karnauskas keeps a Buy rating on Tesaro.
07/19/17
FBCO
07/19/17
NO CHANGE
Target $198
FBCO
Outperform
Tesaro selloff a buying opportunity, says Credit Suisse
Credit Suisse analyst Alethia Young thinks that the selloff in Tesaro shares is overdone. Based on her valuation, the analyst says current share price levels suggest only credit is being given to ovarian cancer and very limited M&A value. Young reiterates an Outperform rating and $198 price target on the shares.
TKPYY Takeda Pharmaceutical Co. Ltd.
$26.30

0.645 (2.51%)

01/11/17
RHCO
01/11/17
DOWNGRADE
RHCO
Hold
ARIAD downgraded following deal at SunTrust
As noted earlier, SunTrust downgraded ARIAD (ARIA) to Hold from Buy. Analyst Yatin Suneja downgraded the shares after the company agreed to be acquired by Takeda (TKPYY). The analyst expects the deal to close. Target to $24 from $22.
01/17/17
PIPR
01/17/17
NO CHANGE
Target $15
PIPR
Overweight
Array BioPharma strength likely aided by M&A speculation, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff noted that Array BioPharma (ARRY) shares hit a 52-week high during Friday's trading, which he attributes to M&A speculation following Ariad's (ARIA) agreement to be acquired by Takeda (TKPYY). Tenthoff, who sees several business development opportunities for Array, reiterates his Overweight rating and $15 price target on the shares.
01/31/17
01/31/17
NO CHANGE

Exelixis down with licensing deal seen as impacting takeover potential
Shares of Exelixis (EXEL) are moving lower after the company last night announced a licensing agreement for the commercialization and further clinical development in Japan of cabozantinib, its oncology medicine, with Takeda Pharmaceutical (TKPYY). Deutsche Bank analyst Andrew Peters said earlier today that while Exelixis' licensing agreement is "clearly encouraging" and highlights the value of cabozantinib, the news could impact "near-term expectations regarding strategic activity, as Japanese rights would be similarly valuable to maintain." Exelixis is down 4%, or 66c, to $17.62 in afternoon trading, a sign that the deal with Takeda could be dampening investor expectations of a buyout in the near-term. The company maintaining the U.S. rights is key, Peters told investors in a research note, adding that the U.S. is core to the valuation and the company's strategic positioning. The analyst has a Buy rating on Exelixis with a $20 price target.
02/06/17
02/06/17
UPGRADE
Target $67

Outperform
PRA Health upgraded to Outperform at Credit Suisse
As previously reported, Credit Suisse analyst Erin Wilson Wright upgraded PRA Health (PRAH) to Outperform from Neutral on greater enthusiasm for the company's recent partnership with Takeda (TKPYY), an incrementally more positive outlook for the broader functional outsourcing market, and relatively healthy CRO industry fundamentals. The analyst also raised her price target on PRA Health's shares to $67 from $50.

TODAY'S FREE FLY STORIES

DE

Deere

$123.98

-2.65 (-2.09%)

06:40
08/18/17
08/18
06:40
08/18/17
06:40
Earnings
Deere raises FY17 net sales and revenue guidance to up 11% from up 9% »

Company equipment sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 22

    Nov

PNM

PNM Resources

$41.70

-0.3 (-0.71%)

06:39
08/18/17
08/18
06:39
08/18/17
06:39
Downgrade
PNM Resources rating change  »

PNM Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$105.92

-0.92 (-0.86%)

06:38
08/18/17
08/18
06:38
08/18/17
06:38
Periodicals
Chevron withdraws appeal of Australian tax bill, Reuters says »

Chevron has decided to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

LB

L Brands

$37.55

-1.4 (-3.59%)

06:38
08/18/17
08/18
06:38
08/18/17
06:38
Recommendations
L Brands analyst commentary  »

L Brands dividend yield…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$123.98

-2.65 (-2.09%)

06:36
08/18/17
08/18
06:36
08/18/17
06:36
Earnings
Breaking Earnings news story on Deere »

Deere raises FY17 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 22

    Nov

HSY

Hershey

$107.85

1.81 (1.71%)

06:35
08/18/17
08/18
06:35
08/18/17
06:35
Recommendations
Hershey analyst commentary  »

Citi says Hershey…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIBB

Hibbett Sports

$11.50

-0.3 (-2.54%)

06:34
08/18/17
08/18
06:34
08/18/17
06:34
Hot Stocks
Hibbett Sports sees 'continued soft sales' for remainder of FY18 »

The company is updating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

RAVN

Raven

$33.45

-0.975 (-2.83%)

06:34
08/18/17
08/18
06:34
08/18/17
06:34
Initiation
Raven initiated  »

Raven initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

PACW

PacWest Bancorp

$44.13

-1.63 (-3.56%)

06:34
08/18/17
08/18
06:34
08/18/17
06:34
Initiation
PacWest Bancorp initiated  »

PacWest Bancorp initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATY

Cathay General

$34.97

-0.94 (-2.62%)

06:34
08/18/17
08/18
06:34
08/18/17
06:34
Initiation
Cathay General initiated  »

Cathay General initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIBB

Hibbett Sports

$11.50

-0.3 (-2.54%)

06:33
08/18/17
08/18
06:33
08/18/17
06:33
Hot Stocks
Hibbett Sports CEO says 'experienced a very difficult retail environment' in Q2 »

Jeff Rosenthal, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

DE

Deere

$123.98

-2.65 (-2.09%)

06:33
08/18/17
08/18
06:33
08/18/17
06:33
Earnings
Deere reports Q3 EPS $1.97, consensus $1.95 »

Reports Q3 net sales and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 22

    Nov

HIBB

Hibbett Sports

$11.50

-0.3 (-2.54%)

06:32
08/18/17
08/18
06:32
08/18/17
06:32
Earnings
Hibbett Sports cuts FY18 EPS view to $1.25-$1.35 from $2.35-$2.55 »

FY18 consensus $1.74.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

PM

Philip Morris

$115.93

-1.8 (-1.53%)

06:32
08/18/17
08/18
06:32
08/18/17
06:32
Periodicals
India threatens Philip Morris with 'punitive action', Reuters reports »

India's federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTZ

MasTec

$39.20

0.45 (1.16%)

, PWR

Quanta Services

$33.83

-0.44 (-1.28%)

06:32
08/18/17
08/18
06:32
08/18/17
06:32
Upgrade
MasTec, Quanta Services rating change  »

MasTec upgraded to Buy…

MTZ

MasTec

$39.20

0.45 (1.16%)

PWR

Quanta Services

$33.83

-0.44 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIBB

Hibbett Sports

$11.50

-0.3 (-2.54%)

06:31
08/18/17
08/18
06:31
08/18/17
06:31
Earnings
Hibbett Sports reports Q2 EPS (15c), consensus (20c) »

Reports Q2 revenue $188M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

PWR

Quanta Services

$33.83

-0.44 (-1.28%)

06:29
08/18/17
08/18
06:29
08/18/17
06:29
Upgrade
Quanta Services rating change  »

Quanta Services upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMPQ

Umpqua Holdings

$17.02

-0.49 (-2.80%)

06:27
08/18/17
08/18
06:27
08/18/17
06:27
Initiation
Umpqua Holdings initiated  »

Umpqua Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$910.98

-15.98 (-1.72%)

, GOOGL

Alphabet Class A

$927.66

-16.61 (-1.76%)

06:26
08/18/17
08/18
06:26
08/18/17
06:26
Hot Stocks
YouTube TV expands in 14 new U.S. markets, plans to launch in additional markets »

Google has expanded its…

GOOG

Alphabet

$910.98

-15.98 (-1.72%)

GOOGL

Alphabet Class A

$927.66

-16.61 (-1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 24

    Aug

DB

Deutsche Bank

$16.44

-0.6 (-3.52%)

, BAC

Bank of America

$23.64

-0.55 (-2.27%)

06:24
08/18/17
08/18
06:24
08/18/17
06:24
Periodicals
Deutsche Bank, Bank of America settle agency bond rigging lawsuits, Reuters says »

Deutsche Bank (DB) and…

DB

Deutsche Bank

$16.44

-0.6 (-3.52%)

BAC

Bank of America

$23.64

-0.55 (-2.27%)

BNPQY

BNP Paribas

$38.45

-1.05 (-2.66%)

C

Citi

$66.60

-1.11 (-1.64%)

CRARY

Credit Agricole

$8.76

-0.26 (-2.88%)

CS

Credit Suisse

$14.70

-0.28 (-1.87%)

HSBC

HSBC

$47.21

-0.82 (-1.71%)

NMR

Nomura

$5.77

-0.05 (-0.86%)

RY

Royal Bank of Canada

$72.96

-0.65 (-0.88%)

TD

Toronto-Dominion

$50.25

-0.36 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

PNM

PNM Resources

$41.70

-0.3 (-0.71%)

06:23
08/18/17
08/18
06:23
08/18/17
06:23
Downgrade
PNM Resources rating change  »

PNM Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGI

Sinclair Broadcast

$29.75

-0.05 (-0.17%)

, GOOG

Alphabet

$910.98

-15.98 (-1.72%)

06:22
08/18/17
08/18
06:22
08/18/17
06:22
Hot Stocks
Sinclair announces carriage agreement with YouTube TV »

Sinclair Broadcast Group…

SBGI

Sinclair Broadcast

$29.75

-0.05 (-0.17%)

GOOG

Alphabet

$910.98

-15.98 (-1.72%)

GOOGL

Alphabet Class A

$927.66

-16.61 (-1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 24

    Aug

  • 07

    Sep

EVH

Evolent Health

$17.05

-0.2 (-1.16%)

06:22
08/18/17
08/18
06:22
08/18/17
06:22
Recommendations
Evolent Health analyst commentary  »

Evolent Health 29%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

TNXP

Tonix Pharmaceuticals

$2.97

-0.04 (-1.33%)

06:22
08/18/17
08/18
06:22
08/18/17
06:22
Upgrade
Tonix Pharmaceuticals rating change  »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THC

Tenet

$12.65

-0.27 (-2.09%)

06:19
08/18/17
08/18
06:19
08/18/17
06:19
Hot Stocks
Tenet says Randy Simpson, Matt Ripperger resign from the Board of Directors »

Tenet Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.